QIAGEN: Asserting the blockbuster status of the QuantiFERON platform | BUY | EUR36,5(+8%)
QIAGEN - BUY | EUR36,5(+8%)Asserting the blockbuster status of the QuantiFERON platform
2nd QuantiFERON-based test to be ported on DiaSorin Liaison-XL
Strengthening the blockbuster status of QuantiFERON
Supporting QIAGEN long-term growth prospects
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.